Home
Contact Us
Products
Health Conditions
Our Other Websites

 

 

Bonlutin: A comprehensive formula for Arthritis

June 2008
 
ABSTRACT: It is the experience of pain and swelling around the joints that forms the primary definition of arthritis, making this degenerative disease in all its collective manifestations Australia's - and probably the world's - most common cause of disability and chronic pain. Conventional arthritis treatments such as anti-inflammatory and analgesic drugs often fail to provide adequate relief for arthritis sufferers. Consequently, complementary therapies such as glucosamine and chondroitin have found favour. The clinically proven ability of omega-3 fish oils to limit the body's production of inflammatory mediators and help maintain cartilage patency has proven particularly effective for sufferers of rheumatoid and osteoarthritis.

 

KEYWORDS: arthritis, osteoarthritis, rheumatoid arthritis, gout, omega-3, inflammation, decreased joint mobility, joint stiffness, joint pain, glucosamine, chondroitin, fibromyalgia, systemic lupus erythematosis, SLE, lupus

The first sign is chronic pain, usually followed by a loss in mobility and resulting stiffness. Pain manifests itself as a sharp ache, with a burning sensation experienced in muscles and tendons. Crepitus (‘crackling noises’) may occur when joints are moved or touched, while joints may fill with fluid and nearby muscles and tendons go in to spasm.

Arthritis commonly affects the hands, feet, knees, hips and elbows. Stemming from the ancient Greek arthro-, meaning ‘joint,’ +itis, meaning ‘inflammation,’ there are over 100 different types of arthritis with different underlying pathophysiologies – osteroarthritis, rheumatoid arthritis, gouty arthritis, fibromyalgia and systemic lupus erythematosis account for 90% of all cases [1].  It is the experience of pain and swelling around the joints that forms the primary definition of this degenerative disease, making arthritis in all its collective manifestations Australia’s – and probably the world’s – most common cause of disability and chronic pain [2]. 


Aetiology
Wherever two bones articulate with one another in the body, they are generally prevented from rubbing directly against each other by a thin protective layer of cartilage around their heads. This largely collagen-composed layer helps to ensure that bones glide smoothly across one another when they come into contact, a process which is further lubricated by synovial fluid in the knee joint.

As time goes on and people age, the water content in bone cartilage tends to decrease due to a gradual reduction in proteoglycan (aggrecan) levels, leaving the collagen fibres within the cartilage more open to degradation. As the water and collagen within the cartilage deteriorates, the cartilage itself becomes less resilient, losing its elastic properties and allowing bone to grind against bone. This is one of the primary causes for inflammation in the most common form of arthritis: osteoarthritis.

New adventitious bone outgrowths, known as osteophytes (or ‘spurs’), may accompany this condition, causing further pain and inflammation and impeding normal movement as they grind against bone, muscle and tendons.

Rheumatoid arthritis is a systemic auto-immune disorder affecting mainly the synovial joints. As part of an aberrant immune reaction triggered by an as yet unidentified mediator, pro-inflammatory cytokines are produced and begin to attack the non-cartilaginous joint lining (synovium), bone and cartilage itself, giving rise to severe pain and inflammation. As an immune reaction, this process is systemic, commonly affecting multiple joints and eventually leading to deformities and other severe complications.


 
Figure 1. The signs of rheumatoid arthritis. An elderly woman with the finger and wrist deformities that are characteristic of this debilitating disorder.


Treatment
Because arthritis is a degenerative condition, in most cases it is irreversible, and is in fact likely to only get worse over time. Consequently, the vast majority of modern arthritis treatments focus on the management and relief of the symptoms associated with the condition: joint pain and inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics have therefore become the cornerstones of all arthritis treatment regimes [3].  Yet, unfortunately, these medications fail to provide a sufficient level of relief to many arthritis sufferers.

A considerable amount of interest in complementary and adjuvant therapies for arthritis has emerged in recent years, with glucosamine and chondroitin therapeutics proving particularly popular and effective for many individuals. The relatively recent discovery that fish oils can also help to provide effective relief from the symptoms of arthritis is less well known.

Fish Oils (Omega-3 Marine Triglycerides)
Omega-3 marine triglycerides are considered to be essential fatty acids – they are essential for human health, but cannot be manufactured by the body. It is therefore necessary to obtain these acids from food, with fish (particularly fatty fish such as salmon, tuna, herring and mackerel) providing an excellent source.

There are three key types of omega-3 fatty acids that are used by the human body: alpha-linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Once ingested, ALA tends to be converted into the 20- and 22-carbon fatty acids DHA and EPA, the two forms of omega-3 most favoured by the human body. Research has shown that these omega-3 fatty acids may be useful in reducing the risk of cardiovascular disease, cancer and inflammation associated with arthritis.

 

Fish Oils and Rheumatoid Arthritis
There is a sound biological basis for the benefit of fish oils in the treatment of rheumatoid arthritis. Eicosanoids, which are among the key substances that mediate the intensity and duration of inflammation, are derived from 20-carbon polyunsaturated fatty acids (PUFAs). Because inflammatory cells usually contain a high proportion of the 20-carbon omega-6 arachidonic acid (AA) compared to other omega-6 20-carbon PUFAs (20:4), AA is usually the major substrate for eicosanoid synthesis during inflammation.

The pro-inflammatory eicosanoids prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are both derived from AA. However, EPA (contained in fish oils) can act as a competitive inhibitor of AA conversion to PGE2 and LTB4 (see Figure 2). Comprehensive studies have therefore demonstrated the effectiveness of omega-3 fatty acids in decreasing the production of pro-inflammatory substances such as prostaglandins, leukotrienes and cytokines, all of which are associated with the inflammatory response accompanying arthritis [4].


Figure 2. EPA Competitively inhibits the conversion of Arachidonic Acid to pro-inflammatory PGE2, TXA2 and LTB4. In this diagram, cyclo-oxygenase (COX) catalyses the conversion of AA to PGH2, while 5-Lipo-oxygenase catalyses AA’s conversion to LTB4. EPA competes for COX and 5-LOX at both these steps, competitively inhibiting the production of inflammatory prostaglandins, thromboxane and leukotrienes.


In recent years, these studies have been supported by a considerable number of clinical trials in which patients suffering from the effects of arthritis have experienced significant improvements in outcome measures such as tender joints, morning stiffness, grip strength and the interval to fatigue onset [5].

Fish Oils on Osteoarthritis
As mentioned previously, one of the key features of the progression of osteoarthritis involves a reduction in cartilage proteoglycans (aggrecans), which leads to cartilage degradation. The catabolism of the aggrecan contained within cartilage is mediated by the activity of proteolytic enzymes known as aggrecanases.

Aggrecanase activity is upregulated by the exposure of cartilage to pro-inflammatory cytokines such as interleukins-1 and tumour necrosis factor-a, which in turn stimulate the autocrine production of cartilage cytokines, potentiating the degradation process. However, omega-3 fatty acids have also been shown to specifically limit the expression and activity of both aggrecanases and pro-inflammatory cytokines [6].  This evidence for a cartilage-protective effect mediated by fish oils provides a further basis for the benefits of omega-3 fatty acids in the treatment of osteo- and rheumatoid arthritis.

Glucosamine
Glucosamine plays an important role in cartilage health and resilience and is a naturally occurring long chain amino-sugar molecule. It is the major building block of proteoglycans, and is used in the formation of glycosaminoglycans, which bind water within the structure of cartilage and give cartilage its flexible and protective properties. Glucosamine also stimulates collagen production.

Glucosamine has been proven to be at least equal to conventional NSAID therapy for osteoarthritis, with over 20 controlled clinical trials with more than 6000 participants judging it to be effective as a treatment for the relief of pain and functional impairment.  It also has a particularly safe toxicity profile, and may be used in conjunction with conventional anti-inflammatory and analgesic treatments, making it an attractive adjuvant therapy option for the management of arthritis.

Chondroitin
The effectiveness of chondroitin and glucosamine as co-factors has been clinically proven.  Acting as a water and nutrient attractant, chondroitin assists in improving and maintaining adequate levels of synovial fluid in the joints.

Chondrotin is normally the most abundant glycosaminoglycan in the cartilage matrix, and is responsible for binding with collagen, improving and maintaining the strength and cushioning properties of cartilage.

Bonlutin is a novel treatment formula combining fish oil, glucosamine and chondroitin for the management of osteo- and rheumatoid arthritis. It may assist with alleviating joint inflammation, swelling and pain associated with arthritis, while increasing joint mobility. Its other benefit including assistance for muscular aches, pains and cramps and the management of soft tissue trauma, providing relief from the symptoms of tenosynovitis and fibromyalgia.

For more information about Bonlutin, please click here

 
[1] Access Economics Pty Ltd Canberra ACT for The Arthritis Foundation of Australia (2001) The Prevalence, Cost and Disease Burden of Arthritis in Australia
<http://www.arthritisaustralia.com.au/media/file/Access%20Economics%20Report%202001.pdf> (Accessed on 29/02/2008) p.2

[2] Ibid, p.1.

[3] O'Dell J (2004) Therapeutic strategies for rheumatoid arthritis, New England Journal of Medicine 350(25): 2591-602.

[4] James MJ, Gibson RA, Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production, American Journal of Clinical Nutrition, 71 (Supp): 343S-348S.

[5] Cleland LG, James MJ (2002) Rheumatoid Arthritis, Medical Journal of Australia, 176 (Supp): S119-S120.

[6] Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B (2000) n-3 Fatty Acids Specifically Modulate Catabolic Factors Involved in Articular Cartilage Degradation, The Journal of Biological Chemistry 275(2):721-4.

About Us   |    Research Reviews   |    Health Updates   |    Ask A Naturopath   |    Member Area   |    Site Search   |    Sitemap   |    Conditions of Use

© Max Biocare 2008